US FDA approves Jardiance to treat adults living with heart failure with reduced ejection fraction
Heart failure accounts for more than one million hospitalisations a year in the US
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Boehringer Ingelheim
Pharma industry’s digital maturity has accelerated with the adoption of digital engagement channels
Shashin Bodawala, Director – Business Excellence, Boehringer Ingelheim India updates Viveka Roychowdhury on the evolution of…
Aragen expands discovery research pact with Boehringer Ingelheim
Aragen will dedicate a sizeable portion of its campus in Hyderabad to support this alliance
European Commission approves Jardiance to treat heart failure
This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 per cent reduction in the combined…
New products to drive systemic sclerosis market to $1.8 bn by 2030: GlobalData
GlobalData expects Ofev and Actemra/RoActemra to reach peak global sales of $508.8 million in 2025 and $163.2 million in 2024,…
Lupin announces achievement of key milestones for its clinical stage MEK inhibitor compound
Lupin’s MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor…
Boehringer Ingelheim allocates one million Euros to fight COVID-19 in India
The package to focus on medical, sustenance support
Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD…
Boehringer Ingelheim India has shared its roadmap of partnerships and patient access programmes to sustain its growth momentum in…
Boehringer Ingelheim, Enara Bio sign pact to discover novel shared antigens for cancer…
Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers
Boehringer Ingelheim appoints Vani Manja as Country MD for India
She was formerly the Global Head of Boehringer Ingelheim’s Go-To-Market and Business Steering organisation, based in the company’s…